CBI member GSK has announced that its Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) has been approved by the China Food and Drug Administration (CFDA), for the treatment of mild to moderate asthma acute exacerbations in children and adolescents aged 4 – 16 years.
Flixotide Nebules can significantly improve lung function and relieve acute symptoms through continuous strong anti-inflammatory effect.
Dr. Wim Swyzen, VP and Country Medical Director for GSK China said: “It’s medically important and critical to prevent and adequately manage asthma and exacerbations in children.
The approval of Flixotide Nebules provides an important option to help relieve acute symptoms for Chinese children with asthma and effectively reduce application of systemic corticosteriods.”
Please read more here.
Comments